Beyond the expected hyperactivation of downstream signaling pathways such as ERK/MAPK and PI-3K/AKT, there remains a paucity of research into identifying prominent molecular targets that could be of therapeutic benefit in tamoxifen-refractory HRG+/HER2− luminal B-like breast carcinoma. Here, HRG is linked to breast carcinoma.